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Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and
has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection
of Clostridium difficile isolates and report uniformly high MICs (>256g/ml) to C/T.
In December of 2014, ceftolozane-tazobactam received U.S.Food and Drug Administration (FDA) approval for the treat-
ment of complicated intra-abdominal infections (cIAI) and com-
plicated urinary tract infections (cUTI) (http://www.fda.gov
/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm).
Ceftolozane-tazobactam is a novel-lactam/-lactamase inhibitor
combination with activity against Pseudomonas aeruginosa, ex-
tended-spectrum -lactamase (ESBL)-producing Enterobacteria-
ceae, and members of the Streptococcus anginosus group (1). The
activity of ceftolozane-tazobactam against anaerobic bacteria is
varied. For example, the MIC90 of 244 Bacteroides fragilis isolates,
86 Bacteroides thetaiotaomicron isolates, and 12 Fusobacterium
species isolates was 4 g/ml, 32 g/ml, and 0.25 g/ml, respec-
tively (2).
Clostridium difficile infection (CDI) is well documented as a
potential adverse consequence of antimicrobial therapy with a
cephalosporin (3–5). The incidence and severity of CDI have in-
creased in recent years, resulting in significant morbidity, mortal-
ity, and cost to the health care system (6, 7). C. difficile is classified
as one of only three urgent, or highest priority, multidrug-resis-
tant microbial threats by the Centers for Disease Control and Pre-
vention (http://www.cdc.gov/drugresistance/threat-report-2013/).
To date, limited clinical data regarding ceftolozane-tazobactam
therapy exist, and the risk of CDI following therapy with this spe-
cific agent is relatively understudied. In two of the clinical trials
that evaluated ceftolozane-tazobactam treatment of cIAI (8) and
cUTI (9), 3 cases of CDI were documented (1% incidence).
In light of the varied antianaerobic activity of ceftolozane-ta-
zobactam, an assessment of the antimicrobial resistance profile for
ceftolozane-tazobactam with C. difficile could be important for
understanding the potential risk of developing CDI during ther-
apy with this agent. A recent study by Snydman et al. (2) evaluated
the activity of ceftolozane-tazobactam against a large collection of
anaerobic bacteria using agar dilution; this collection included 30
isolates of C. difficile. The MIC range of ceftolozane-tazobactam
against the C. difficile isolates was 0.25g/ml to256g/ml, and
the MIC50 was 256 g/ml (2). In contrast, the MIC range and
MIC50 documented for Clostridiumperfringens (n 11) and other
Clostridium spp. (n 13) were lower (MIC50, 0.25 g/ml and 16
g/ml, respectively) (2). Currently, there are no categorical inter-
pretative criteria for ceftolozane-tazobactam MICs for Clostrid-
ium species. It is well documented that the overall antimicrobial
resistance profiles of C. difficile strains can vary widely among
different strain types (10–12). Unfortunately, no C. difficile strain
typing data were available as part of the Snydman et al. study (2),
and thus it was unknown if this profile was generalizable to differ-
ent C. difficile strain types.
The objective of our study was to evaluate the antimicrobial
activity of ceftolozane-tazobactam against a diverse collection of
C. difficile strain types. The isolates investigated were recovered
from fecal specimens or rectal swab specimens from patients at
Barnes-Jewish Hospital from January 2010 to July 2012. Speci-
mens were collected as part of other ongoing studies to assess C.
difficile diagnostic assays, C. difficile infection, or asymptomatic
colonization (3, 10, 13, 14). C. difficile isolates were recovered in
culture (15) and ribotyped (16), as previously described.
All isolates were recovered from frozen stocks and were sub-
cultured twice on prereduced 5% sheep blood agar (Hardy Diag-
nostics, Santa Maria, CA) in an anaerobic environment prior to
testing. The identity of each C. difficile isolate was confirmed by
matrix-assisted laser desorption ionization–time of flight mass
spectrometry (MALDI-TOF MS) using the Vitek MS (IVD ver-
sion 2.3.3; bioMérieux, Durham, NC) (17). Ceftolozane-tazobac-
tam susceptibility testing was performed using a gradient diffu-
sion method (Etest; bioMérieux, Durham, NC), according to the
manufacturer’s recommendations. In brief, a 1 McFarland stan-
dard suspension of each isolate was prepared in 0.9% saline and
plated as a lawn onto brucella blood agar with hemin and vitamin
K (Hardy Diagnostics), and ceftolozane-tazobactam Etest strips
were applied. The plates were incubated under anaerobic condi-
tions and read at 24 and 72 h of incubation. During each day of
analysis, the quality control strain B. fragilis ATCC 25285 (accept-
able quality control [QC] range, 0.12 to 1 g/ml) was tested.
Eighty-one C. difficile isolates were tested, representing 15 dif-
ferent ribotypes (Table 1). Of note, our test set included 26 C.
difficile ribotype 027 (NAP1/BI/ST-1) strains and 3 C. difficile ri-
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botype 078 isolates. These strain types are currently among the
most common ribotypes in North America and parts of Europe
(18, 19); the toxigenic status of each ribotype was determined by
phenotypic (i.e., toxin enzyme immunoassays) and/or genotypic
methods (3, 10, 13, 14).
Ceftolozane-tazobactam demonstrated no activity against any
of the isolates investigated. All isolates tested (n 81) had ceftolo-
zane-tazobactam MICs of 256 g/ml at both the 24- and 72-h
incubation time points. This phenotype appears to be distinct
from that of other Clostridium species (2).
A potential limitation of this study is that all of the isolates
investigated were recovered at a single medical center. However,
this limitation is mitigated by the careful characterization of the
isolates, which demonstrated that a phylogenetically diverse pop-
ulation of strains was tested, and this is a strength of this investi-
gation. The impact of ceftolozane-tazobactam on the gastrointes-
tinal microbiota is unknown at this time. Similar to other
cephalosporins that are documented to be risk factors for devel-
oping CDI (3–5), ceftolozane-tazobactam is predominantly elim-
inated by renal clearance (17). The concentration of this agent in
the stool or the gastrointestinal tract is not known at this time.
In conclusion, we have demonstrated that C. difficile appears to
be uniformly resistant to ceftolozane-tazobactam. Additional
clinical data are needed to appreciate the impact of this agent on
both the intestinal microbiota and the relative risk of developing
CDI during therapy.
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